Perspective Therapeutics (NASDAQ:CATX) Earns Outperform Rating from Wedbush

Perspective Therapeutics (NASDAQ:CATX)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a note issued to investors on Friday,Benzinga reports. They currently have a $11.00 price objective on the stock. Wedbush’s price target would suggest a potential upside of 170.27% from the company’s current price.

A number of other analysts have also commented on the company. B. Riley dropped their price target on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. UBS Group decreased their target price on shares of Perspective Therapeutics from $18.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, November 21st. Truist Financial began coverage on Perspective Therapeutics in a research note on Monday, November 24th. They set a “buy” rating and a $12.00 price objective for the company. BTIG Research reissued a “buy” rating and set a $14.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, January 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Perspective Therapeutics in a research note on Friday. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, Perspective Therapeutics currently has an average rating of “Buy” and an average price target of $11.17.

Perspective Therapeutics Stock Down 4.5%

Shares of CATX stock traded down $0.19 during mid-day trading on Friday, reaching $4.07. The stock had a trading volume of 2,515,574 shares, compared to its average volume of 5,209,135. Perspective Therapeutics has a 52-week low of $1.60 and a 52-week high of $6.16. The company has a market capitalization of $302.56 million, a price-to-earnings ratio of -4.52 and a beta of 1.18. The company has a 50-day moving average price of $2.61.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. UBS Group AG increased its position in shares of Perspective Therapeutics by 44.5% during the 4th quarter. UBS Group AG now owns 926,331 shares of the company’s stock valued at $2,547,000 after purchasing an additional 285,188 shares during the last quarter. Trueblood Wealth Management LLC grew its position in Perspective Therapeutics by 72.4% during the fourth quarter. Trueblood Wealth Management LLC now owns 119,061 shares of the company’s stock valued at $327,000 after buying an additional 50,000 shares during the period. Auctus Advisors LLC purchased a new stake in Perspective Therapeutics during the fourth quarter valued at approximately $87,000. R Squared Ltd bought a new position in Perspective Therapeutics in the fourth quarter worth approximately $44,000. Finally, Taylor & Morgan Wealth Management LLC boosted its stake in shares of Perspective Therapeutics by 6.6% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 97,000 shares of the company’s stock worth $267,000 after acquiring an additional 6,000 shares during the last quarter. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.